Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kemofarmacija d.d. - kapsula, trda - ibrutinib

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kemofarmacija d.d. - kapsula, trda - ibrutinib

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Evropska unija - slovenščina - EMA (European Medicines Agency)

hra pharma rare diseases - ketokonazol - cushingov sindrom - antimikotiki za sistemsko uporabo - ketokonazol hra je indiciran za zdravljenje endogenega cushingovega sindroma pri odraslih in mladostnikih, starejših od 12 let.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - vorikonazol - aspergillosis; candidiasis; mycoses - antimycotics za sistemsko uporabo, triazol derivati - voriconazole je v širokem spektru, triazol protiglivično sredstvo, ter je označena pri odraslih in otrocih, starih dve leti ali več, kot sledi:zdravljenje invazivne aspergillosis;zdravljenje candidaemia v ne-neutropenic bolnikov;zdravljenje fluconazole-odporne resno invazivne candida okužbe (vključno c. krusei);zdravljenje hude glivične okužbe, ki jih povzročajo scedosporium spp. in oxysporum spp. voriconazole soglasju mora biti urejen, predvsem pri bolnikih z napredujočo, morda celo smrtno nevarne okužbe.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - flukonazol - kapsula, trda - flukonazol 100 mg / 1 kapsula - flukonazol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - flukonazol - kapsula, trda - flukonazol 150 mg / 1 kapsula - flukonazol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - flukonazol - kapsula, trda - flukonazol 100 mg / 1 kapsula - flukonazol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - flukonazol - kapsula, trda - flukonazol 50 mg / 1 kapsula - flukonazol